eCardio Diagnostics, a provider of remote arrhythmia monitoring services, has introduced a patient-friendly, wireless monitor eCardio Verite.
The multi-functional monitor features both event and telemetry monitoring capabilities including automatic detection, capturing and communication of asymptomatic events such as atrial fibrillation, bradycardia, tachycardia and cardiac pause.
In addition, physicians prescribing eCardio Verite will experience additional benefits through both enhancements to existing reports and a newly developed report, the Verite Initial Assessment.
The Verite Initial Assessment is provided for the first 24 hours of monitoring and may alleviate the need for preliminary Holter studies, claims the company.
eCardio president and chief executive officer Larry Lawson said the new reports for eCardio Verite reflect what physicians have told the company is desired to provide optimal care to their patients.
"Our nationwide cardiology sales force spends time in practices every day, and those conversations played an integral part in the development of the reports we provide with this new monitor," Lawson added.
